You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An Efficacy Trial of Mobile Technology for Reducing and Preventing Adolescent Suicide

    SBC: OUI THERAPEUTICS INC            Topic: 104

    ABSTRACT Suicide is a leading cause of death in the US and suicide rates have steadily increased. Despite this, there is a paucity of interventions that reduce suicide ideation and behavior. In this project, we seek to enhance a beta version of our suicide prevention digital therapeutic (developed in phase I) and conduct a randomized controlled trial to evaluate the efficacy of the digital therape ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. 2-HOBA for Treatment of Pulmonary Hypertension

    SBC: MTI Biotech Incorporated            Topic: NHLBI

    PROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Expansion and validation of novel mobile app for guiding home modifications for aging in place

    SBC: HomesRenewed Ventures LLC            Topic: R

    PROJECT SUMMARY In this Phase II SBIR, HomesRenewed Ventures, LLC (HRV Washington, DC) will build on our previous efforts to expand and validate an interactive mobile application (APP) for guiding home modifications (environmental interventions) critical to Aging in Place (AiP). Home modifications (HM) are associated with falls preventions, improved activities of daily living (ADLs), and emotional ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Noregen, a regenerative medicine ocular therapeutic

    SBC: Retinal Solutions LLC            Topic: NEI

    ABSTRACT Ischemic retinopathies, such as diabetic retinopathy and retinal vein occlusion, are the leading cause of blindness in the United States. Common features are leaky vessels, swelling, capillary drop out, aberrant vessel growth and retinal detachment. Current treatments include laser ablation, anti-VEGFs and steroids. All are sub-optimal and only serve to slow disease progression and vision ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke

    SBC: NUVOX PHARMA, L.L.C.            Topic: NINDS

    ABSTRACT / PROJECT SUMMARY Stroke affects more than 795,000 patients per year in the US and kills approximately 40,000. Long-term medical care expense for stroke in the US, costs over $34B per year. Large vessel occlusion (LVO) stroke accounts for almost 40% of ischemic strokes but causes 95% of mortality and 62% of long-term dependence. Mechanical thrombectomy (MT), or a combination of MT and tPA ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Platform for the High Throughput Generation and Validation of Affinity Reagents

    SBC: ABBRATECH INC.            Topic: 300

    ABSTRACT We present a complete platform for the rapid generation and validation of recombinant mAbs. The innovations of this proposal include: (1) the pATHENA vector system for overnight conversion of phage display scFv or Fab clones into IgG molecules, (2) the Epivolve method for the isolation of site-specific Abs, (3) the incorporation of yeast display into pATHENA to allow biophysical measureme ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of TP-317 in Ulcerative Colitis

    SBC: Thetis Pharmaceuticals LLC            Topic: 300

    ABSTRACT Ulcerative colitis (UC) is a chronic, relapsing disease characterized by inflammation and ulceration of the colon and rectum that affects approximately 1.5 million people in the United States.1 Unfortunately, existing therapies have significant limitations. 5-ASA or mesalamine, which is approved as first-line therapy for UC, is effective in only 50% of UC patients and corticosteroids are ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Enabling Toxoplasma gondii Kinome Directed Drug Discovery

    SBC: LUCEOME BIOTECHNOLOGIES, L.L.C.            Topic: NIAID

    Project Summary Toxoplasma gondii (T.gondii), the causative agent for toxoplasmosis, invades host cells through ingestion of uncooked infected meat or contaminated water. T.gondii infects 30% of the world’s population and the current cost of the disease in US itself is estimated to be $3B and rising. Current treatment regimen is effective only against acute infection and has severe side effects. ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical Optimization of Ultrasonic Drug Delivery Technologies for Underserved Minority US Veterans in Chronic Pain

    SBC: ZETROZ SYSTEMS, LLC            Topic: 102

    Project Summary: Narcotic use in pain management of underserved minority populations and minority United States veterans has played a major role in the ongoing opioid crisis. According to the NIH, veterans are more susceptible to opioid addiction and are 40% more likely to suffer from severe chronic joint pain then non-veterans. Over the next decade, the percentage of minority veterans will increa ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens

    SBC: Curza Inc            Topic: NIAID

    Project Summary Cūrza is developing the CZ-02 platform of broad-spectrum antibiotics as a new class focusing on multidrug- resistant (MDR) Gram-negative pathogens that will also be efficacious against Gram-positive bacteria. CZ-02 antibacterials bind to a unique site on the bacterial ribosome that is not targeted by antibiotics available clinically which is expected to limit cross-resistance to o ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government